An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) will be presenting at the LSX World Congress 2024 with CEO John Climaco discussing the company's focus on developing novel treatments for brain and CNS cancers. The presentation is scheduled for Monday, April 29th at 4:15 PM (GMT+1) in London, England, followed by one-on-one investor meetings.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) presenterà al Congresso Mondiale LSX 2024, con il CEO John Climaco che discuterà dell'impegno dell'azienda nello sviluppo di nuovi trattamenti per i tumori cerebrali e del sistema nervoso centrale. La presentazione è prevista per lunedì 29 aprile alle 16:15 (GMT+1) a Londra, Inghilterra, seguita da incontri individuali con gli investitori.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) estará presentando en el Congreso Mundial LSX 2024, donde el CEO John Climaco hablará sobre el enfoque de la compañía en el desarrollo de tratamientos innovadores para cánceres del cerebro y del sistema nervioso central. La presentación está programada para el lunes 29 de abril a las 4:15 PM (GMT+1) en Londres, Inglaterra, seguida de reuniones individuales con inversores.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)는 2024 LSX 세계 회의에서 발표할 예정입니다. 회사의 CEO인 존 클리마코가 뇌 및 중추 신경계 암에 대한 새로운 치료법 개발에 대한 회사의 초점에 대해 논의할 것입니다. 발표는 4월 29일 월요일 오후 4시 15분(GMT+1) 영국 런던에서 예정되어 있으며, 이어서 일대일 투자자 미팅이 진행될 예정입니다.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) présentera au Congrès Mondial LSX 2024, avec le PDG John Climaco qui discutera de l'orientation de l'entreprise vers le développement de nouveaux traitements pour les cancers du cerveau et du système nerveux central. La présentation est prévue pour le lundi 29 avril à 16h15 (GMT+1) à Londres, Angleterre, suivie de rencontres individuelles avec les investisseurs.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) wird auf dem LSX Weltkongress 2024 präsentieren, bei dem CEO John Climaco über den Schwerpunkt des Unternehmens auf die Entwicklung neuer Behandlungen für Gehirn- und ZNS-Krebs sprechen wird. Die Präsentation ist für Montag, den 29. April um 16:15 Uhr (GMT+1) in London, England, angesetzt, gefolgt von Einzelgesprächen mit Investoren.
Positive
None.
Negative
None.
Presentation on Monday, April 29th at 4:15 PM (GMT+1)
HOUSTON, TX / ACCESSWIRE / April 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the LSX World Congress 2024 on Monday, April 29, 2024 at 4:15 PM (GMT+1) in London, England.
In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the event, visit the conference website.
A replay of the presentation will be made available on the Company's website, www.CNSPharma.com, following the conclusion of the conference.
About LSX World Congress 2024 The 10th LSX World Congress gathers the founders and CEOs of innovative start-ups through to healthcare giants, and everyone in between. It represents the breadth and depth of the cutting-edge research and technology driving the advances in the industry right now and in the near future. It is an industry-leading gathering with qualified 1:1 partnering at its core, connecting the biotech, healthtech and medtech industry c-suite with the sector's most active pharma, investors and health technology BD&L teams, R&D leaders, KOLs and top tier service companies who are driving the sector forward.
About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
When is CNS Pharmaceuticals presenting at the LSX World Congress 2024?
CNS Pharmaceuticals will be presenting at the LSX World Congress 2024 on Monday, April 29, 2024, at 4:15 PM (GMT+1) in London, England.
Who will be presenting for CNS Pharmaceuticals at the LSX World Congress 2024?
John Climaco, the Chief Executive Officer of CNS Pharmaceuticals, will be presenting at the LSX World Congress 2024.
What is CNS Pharmaceuticals known for?
CNS Pharmaceuticals specializes in developing novel treatments for primary and metastatic cancers in the brain and central nervous system.
Will CNS Pharmaceuticals be available for one-on-one meetings at the LSX World Congress 2024?
Yes, CNS Pharmaceuticals management will be available for one-on-one meetings with registered members of the investor community attending the conference.
cns pharmaceuticals, inc., a biopharmaceutical company, engages in the development of anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. the company's lead drug candidate is berubicin, which completed phase i clinical trial that is used for the treatment of glioblastoma multiforme. it has license agreements with houston pharmaceuticals, inc. and the university of texas m.d. anderson cancer center; and a development agreement with wpd pharmaceuticals inc. cns pharmaceuticals, inc. was founded in 2017 and is based in houston, texas.
